Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs)

Stock Information for Covalon Technologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Covalon Technologies Ltd.

Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results
Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength
Covalon Declares First Ever Special Cash Dividend
Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025
Empowering Nurses with Innovation: Covalon Showcases Patient Safety Solutions to Tackle Preventable Complications at ANCC National Magnet & Pathway Conference
Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON
Covalon Announces Departure of Executive Chair and the Appointment of its Largest Shareholder as New Chair
Evidence-Driven Outcomes and Clinical Innovation Highlight Covalon's Presence at the Association for Vascular Access 2025 Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.